Ignet

Gene Information

Gene symbol: RARB

Gene name: retinoic acid receptor, beta

HGNC ID: 9865

Synonyms: HAP, NR1B2, RRB2

Related Genes

#	Gene Symbol	Number of hits
1	CAP1	1 hits
2	CRABP2	1 hits
3	CTNNB1	1 hits
4	DAXX	1 hits
5	FLNB	1 hits
6	HGF	1 hits
7	JUP	1 hits
8	RARA	1 hits
9	RARG	1 hits
10	RXRG	1 hits
11	TAPBP	1 hits
12	VDR	1 hits
13	VIM	1 hits

Related Sentences

#	PMID	Sentence
1	9777794	Its actions are targeted on 2 retinoic acid receptors (RARs), RAR-beta and RAR-gamma.
2	11757805	No significant difference in mortality was found between diabetics and non-diabetics, for either CAP or HAP.
3	14715861	Clinical and in vitro studies suggest that some patients with advanced thyroid cancer may respond to therapy with retinoic acid. mRNA expression of the six retinoic acid (RAR) and retinoid X receptor (RXR) isoforms (RARalpha, -beta, -gamma and RXRalpha, -beta, -gamma) was measured in four human thyroid cell lines, and protein expression was subsequently measured in 10 thyroid cancer cell lines.
4	14715861	Two isoforms, RARbeta and RXRgamma, were differentially expressed in the four cell lines.
5	14715861	Comparison of 10 thyroid tumors and matched normal thyroid tissue confirmed differential tumor expression of RARbeta and RXRgamma and lack of the RXRgamma isoform in normal thyroid tissue.
6	14715861	Cell lines expressing both RARbeta and RXRgamma demonstrated significant growth suppression when treated with retinoids, whereas cell lines lacking these isoforms were unaffected.
7	14715861	In summary, we identified the RARbeta and RXRgamma isoform to be differentially expressed in thyroid cancer cell lines and tumor tissue.
8	14715861	Clinical and in vitro studies suggest that some patients with advanced thyroid cancer may respond to therapy with retinoic acid. mRNA expression of the six retinoic acid (RAR) and retinoid X receptor (RXR) isoforms (RARalpha, -beta, -gamma and RXRalpha, -beta, -gamma) was measured in four human thyroid cell lines, and protein expression was subsequently measured in 10 thyroid cancer cell lines.
9	14715861	Two isoforms, RARbeta and RXRgamma, were differentially expressed in the four cell lines.
10	14715861	Comparison of 10 thyroid tumors and matched normal thyroid tissue confirmed differential tumor expression of RARbeta and RXRgamma and lack of the RXRgamma isoform in normal thyroid tissue.
11	14715861	Cell lines expressing both RARbeta and RXRgamma demonstrated significant growth suppression when treated with retinoids, whereas cell lines lacking these isoforms were unaffected.
12	14715861	In summary, we identified the RARbeta and RXRgamma isoform to be differentially expressed in thyroid cancer cell lines and tumor tissue.
13	14715861	Clinical and in vitro studies suggest that some patients with advanced thyroid cancer may respond to therapy with retinoic acid. mRNA expression of the six retinoic acid (RAR) and retinoid X receptor (RXR) isoforms (RARalpha, -beta, -gamma and RXRalpha, -beta, -gamma) was measured in four human thyroid cell lines, and protein expression was subsequently measured in 10 thyroid cancer cell lines.
14	14715861	Two isoforms, RARbeta and RXRgamma, were differentially expressed in the four cell lines.
15	14715861	Comparison of 10 thyroid tumors and matched normal thyroid tissue confirmed differential tumor expression of RARbeta and RXRgamma and lack of the RXRgamma isoform in normal thyroid tissue.
16	14715861	Cell lines expressing both RARbeta and RXRgamma demonstrated significant growth suppression when treated with retinoids, whereas cell lines lacking these isoforms were unaffected.
17	14715861	In summary, we identified the RARbeta and RXRgamma isoform to be differentially expressed in thyroid cancer cell lines and tumor tissue.
18	14715861	Clinical and in vitro studies suggest that some patients with advanced thyroid cancer may respond to therapy with retinoic acid. mRNA expression of the six retinoic acid (RAR) and retinoid X receptor (RXR) isoforms (RARalpha, -beta, -gamma and RXRalpha, -beta, -gamma) was measured in four human thyroid cell lines, and protein expression was subsequently measured in 10 thyroid cancer cell lines.
19	14715861	Two isoforms, RARbeta and RXRgamma, were differentially expressed in the four cell lines.
20	14715861	Comparison of 10 thyroid tumors and matched normal thyroid tissue confirmed differential tumor expression of RARbeta and RXRgamma and lack of the RXRgamma isoform in normal thyroid tissue.
21	14715861	Cell lines expressing both RARbeta and RXRgamma demonstrated significant growth suppression when treated with retinoids, whereas cell lines lacking these isoforms were unaffected.
22	14715861	In summary, we identified the RARbeta and RXRgamma isoform to be differentially expressed in thyroid cancer cell lines and tumor tissue.
23	15379720	In vitro studies suggest that the retinoid receptors (RARbeta and RXRgamma) are required for this effect.
24	17389020	We selected five single nucleotide polymorphisms in genes with potential immune-related functions in the genomic regions of death-domain-associated protein 6 (DAXX, apoptosis associated), TAP-binding protein (TAPBP, human leukocyte antigen class I loading) and retinoic acid receptor beta (RXRB, vitamin D receptor function) that may bear relevance to the pathogenesis of T1D.
25	20197308	Proinsulin C-peptide antagonizes the profibrotic effects of TGF-beta1 via up-regulation of retinoic acid and HGF-related signaling pathways.
26	20197308	Expression of retinoic acid receptor beta (RARbeta), hepatocyte growth factor (HGF), cellular retinoic acid-binding protein II (CRABPII), vimentin, E-cadherin, Snail, and beta-catenin was assessed by immunoblotting.
27	20197308	The cellular localization of vimentin and beta-catenin was determined by immunocytochemistry.
28	20197308	Immunoblotting demonstrated that C-peptide increased RARbeta, CRABPII, and HGF.
29	20197308	Further, effects of TGF-beta1 on Snail and E-cadherin expression were blocked by HGF, and inhibitory effects of C-peptide were removed by blockade of HGF activity.
30	20197308	Proinsulin C-peptide antagonizes the profibrotic effects of TGF-beta1 via up-regulation of retinoic acid and HGF-related signaling pathways.
31	20197308	Expression of retinoic acid receptor beta (RARbeta), hepatocyte growth factor (HGF), cellular retinoic acid-binding protein II (CRABPII), vimentin, E-cadherin, Snail, and beta-catenin was assessed by immunoblotting.
32	20197308	The cellular localization of vimentin and beta-catenin was determined by immunocytochemistry.
33	20197308	Immunoblotting demonstrated that C-peptide increased RARbeta, CRABPII, and HGF.
34	20197308	Further, effects of TGF-beta1 on Snail and E-cadherin expression were blocked by HGF, and inhibitory effects of C-peptide were removed by blockade of HGF activity.